Relation of Baseline Neutrophil Gelatinase-Associated Lipocalin (NGAL) Levels and Contrast-Induced Nephropathy following Percutaneous Coronary Intervention among Chronic Kidney Disease Patients.
ST-elevation myocardial infarction (STEMI)
acute kidney injury (AKI)
chronic kidney disease (CKD)
neutrophil gelatinase-associated lipocalin (NGAL)
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
19 Nov 2021
19 Nov 2021
Historique:
received:
21
10
2021
revised:
04
11
2021
accepted:
17
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
The risk of contrast-induced acute kidney injury (CI-AKI) following coronary intervention is particularly high among patients with chronic kidney disease (CKD). Among these patients, baseline neutrophil gelatinase-associated lipocalin (NGAL), a marker of tubular damage, reflects the severity of renal impairment. We evaluated whether the baseline serum NGAL level may be a marker for the development of CI-AKI following percutaneous coronary intervention (PCI). Eighty-eight CKD patients treated with PCI were included. Serum NGAL levels were drawn upon hospital admission. Receiver operator characteristic (ROC) methods were used to identify the optimal sensitivity and specificity for the observed NGAL level compared with the estimated glomerular filtration rate (eGFR) calculated for patients with CI-AKI. Overall CI-AKI incidence was 43%. Baseline serum NGAL levels were significantly higher in patients with CI-AKI than in patients without CI-AKI (150 vs. 103 ng/mL, Baseline serum NGAL levels in CKD patients may identify a high-risk population for CI-AKI following PCI. Further studies on larger populations are required to validate the potential utility of NGAL measurements in monitoring specific CKD-associated conditions.
Sections du résumé
BACKGROUND
BACKGROUND
The risk of contrast-induced acute kidney injury (CI-AKI) following coronary intervention is particularly high among patients with chronic kidney disease (CKD). Among these patients, baseline neutrophil gelatinase-associated lipocalin (NGAL), a marker of tubular damage, reflects the severity of renal impairment. We evaluated whether the baseline serum NGAL level may be a marker for the development of CI-AKI following percutaneous coronary intervention (PCI).
METHODS
METHODS
Eighty-eight CKD patients treated with PCI were included. Serum NGAL levels were drawn upon hospital admission. Receiver operator characteristic (ROC) methods were used to identify the optimal sensitivity and specificity for the observed NGAL level compared with the estimated glomerular filtration rate (eGFR) calculated for patients with CI-AKI.
RESULTS
RESULTS
Overall CI-AKI incidence was 43%. Baseline serum NGAL levels were significantly higher in patients with CI-AKI than in patients without CI-AKI (150 vs. 103 ng/mL,
CONCLUSION
CONCLUSIONS
Baseline serum NGAL levels in CKD patients may identify a high-risk population for CI-AKI following PCI. Further studies on larger populations are required to validate the potential utility of NGAL measurements in monitoring specific CKD-associated conditions.
Identifiants
pubmed: 34830685
pii: jcm10225403
doi: 10.3390/jcm10225403
pmc: PMC8626017
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Pediatr Nephrol. 2007 Dec;22(12):2089-95
pubmed: 17874137
Nephrol Dial Transplant. 2008 Jan;23(1):414-6
pubmed: 17893105
Am J Nephrol. 2007;27(4):373-8
pubmed: 17570904
Int J Inflam. 2012;2012:189797
pubmed: 22988542
Clin J Am Soc Nephrol. 2010 Dec;5(12):2154-65
pubmed: 20798258
Curr Opin Nephrol Hypertens. 2006 Jul;15(4):442-9
pubmed: 16775460
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Curr Protein Pept Sci. 2017;18(12):1211-1217
pubmed: 27634444
Am J Kidney Dis. 2008 Sep;52(3):425-33
pubmed: 18649981
Am J Kidney Dis. 2008 Sep;52(3):595-605
pubmed: 18725016
J Nephrol. 2018 Jun;31(3):423-428
pubmed: 29185210
Am J Kidney Dis. 2009 Dec;54(6):1012-24
pubmed: 19850388
Turk J Emerg Med. 2017 Jun 03;17(3):85-88
pubmed: 28971154
Ren Fail. 2018 Nov;40(1):547-553
pubmed: 30278796
Nephron Clin Pract. 2008;108(3):c176-81
pubmed: 18287807
Ann Clin Biochem. 2014 May;51(Pt 3):335-51
pubmed: 24518531
Crit Care. 2013 Feb 04;17(1):204
pubmed: 23394211
Kidney Blood Press Res. 2007;30(6):408-15
pubmed: 17901710
Ren Fail. 2001 May-Jul;23(3-4):551-62
pubmed: 11499569
Crit Care Med. 2010 Feb;38(2):438-44
pubmed: 19789449
Kidney Blood Press Res. 2014;39(6):623-9
pubmed: 25531230
Kidney Blood Press Res. 2008;31(4):255-8
pubmed: 18600028
Clin Res Cardiol. 2014 Jul;103(7):525-32
pubmed: 24522799
Arch Intern Med. 2008 May 12;168(9):987-95
pubmed: 18474763
Kidney Int. 2014 Mar;85(3):513-21
pubmed: 24107851
Kidney Int. 2007 May;71(10):967-70
pubmed: 17342180